Data from the BREEZE open-label extension study of Tyvaso DPI detail its long-term outcomes and dosing in patients with pulmonary arterial hypertension.
United Therapeutics Plans Five Presentations And One Poster Across Its Commercial And Development Portfolio At The CHEST 2024 Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.